Mettre fin à la guerre contre la drogue : Rapport du Groupe d’Experts de la LSE sur l’ Economie de la Politique des Drogues

Publications

Mettre fin à la guerre contre la drogue : Rapport du Groupe d’Experts de la LSE sur l’ Economie de la Politique des Drogues

14 mai 2014

Il est temps de mettre fin à la « guerre contre la drogue » et de rediriger les ressources vers des politiques effectives fondées sur des preuves et renforcées par des analyses économiques rigoureuses. Pour en savoir plus, veuillez lire les informations ci-dessous (en anglais).

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

It is time to end the ‘war on drugs’ and massively redirect resources towards effective evidence-based policies underpinned by rigorous economic analysis.

The pursuit of a militarised and enforcement-led global ‘war on drugs’ strategy has produced enormous negative outcomes and collateral damage. These include mass incarceration in the US, highly repressive policies in Asia, vast corruption and political destabilisation in Afghanistan and West Africa, immense violence in Latin America, an HIV epidemic in Russia, an acute global shortage of pain medication and the propagation of systematic human rights abuses around the world.

The strategy has failed based on its own terms. Evidence shows that drug prices have been declining while purity has been increasing. This has been despite drastic increases in global enforcement spending. Continuing to spend vast resources on punitive enforcement-led policies, generally at the expense of proven public health policies, can no longer be justified.

The United Nations has for too long tried to enforce a repressive, ‘one-size-fits-all’ approach. It must now take the lead in advocating a new cooperative international framework based on the fundamental acceptance that different policies will work for different countries and regions.

This new global drug strategy should be based on principles of public health, harm reduction, illicit market impact reduction, expanded access to essential medicines, minimisation of problematic consumption, rigorously monitored regulatory experimentation and an unwavering commitment to principles of human rights.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.